Perrigo Receives Final Approval From FDA For Polyethylene Glycol 3350

Perrigo has received final approval from the FDA for its Abbreviated New Drug Application for over-the-counter Polyethylene Glycol 3350, Powder for Solution. Perrigo is expecting to begin shipping immediately.

Reportedly, the product will be marketed under store brand labels and is comparable to Schering-Plough HealthCare Products’ Miralax, indicated for the treatment of occasional constipation.

Joseph Papa, chairman and CEO of Perrigo, said: “It is investments like this that help save OTC healthcare consumers more than an estimated $1billion annually when compared to the higher priced national brands.”

Perrigo is a global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products.